Siemens and Merck have announced an extension of their strategic partnership aimed at advancing the use of artificial intelligence and data-driven solutions in drug discovery and development. The collaboration seeks to accelerate the transition from laboratory research to therapies for patients by integrating Merck’s software-as-a-service products with Siemens’ digital platforms.
Jean-Charles Wirth, Member of the Executive Board and CEO Life Science at Merck, stated, “Through this collaboration with Siemens, we are opening new possibilities for scientists to move faster from an idea in the lab to a therapy for patients. By combining our strengths, we aim to change how science advances, unlocking new ways to accelerate scientific progress.”
Cedrik Neike, Member of the Managing Board at Siemens AG and CEO of Siemens Digital Industries, added, “We are partnering with Merck to give scientists around the world the instruments to speed up the development of life-saving medication. Every few years the cost for developing a new drug is doubling. Data, AI and digitalization are key to break this paradigm. We are connecting every step of drug development through a digital backbone – so that data flows seamlessly, insights emerge faster, and medication reaches the patients faster.”
The initial phase will involve making Merck’s AI tools available on Luma, Siemens’ Scientific Intelligence Platform acquired as part of Dotmatics. This integration is intended to provide scientists with a unified environment that connects product ordering with immediate access to digital tools needed for faster decision-making.
Both companies plan further joint projects aimed at co-developing advanced data management tools and user-friendly interfaces for scientists. They are also considering creating digital marketplaces where customers can access complementary technologies and services efficiently.
The partnership builds on previous agreements between Merck and Siemens in smart manufacturing and underscores both organizations’ commitment to fostering innovation in life sciences through digital transformation.